The most effective and least toxic antisicking are likly to be those that react with Hbs specifically at the contact sites responsible for polymerization. Using a variety of experimental and computational techniques, we have recently developed a sucessful design strategy for site-direted targeting of Hbs polymerization inhibitors that provides competitive inhibiton of Hbs polymerization through binding to a specific region close to the 2,3-BPG binding site and the lateral """"""""acceptor"""""""" contact site on the Hbs molecule. We now propose to pursue two approaches to design and develop new antisicking agents that act specifically at this site. The first is based on our recent identification of several currently approved drugs that are also hihly active inhibitors of Hbs polymerization. We propose new structural modifictions to include our covalent targeting strategy. Both the native drug and the covalent derivatives will be studied for effectiveness and specificity. The secons approach will be based on a series of mixed phosphate anhydrides that are structurally related to BPG and are predicated to have a high affinity for its bindin site, providing an alternative targeting strategy. The rates and extent of HbA abd HbS modification by covalent agents will be determies. Modified peptidues will be isolated from globins, and sequenced to determine the speicfic modification sites. NMT and X-ray crystallography will be used to determine the inhibitors binding geometries of modified Hb. Results will be compared to those predicated by our computer model, in order to design new agents having enhanced affinity and specifity, and to improve the predictive power of the model. Functional properties of modified hemoglobins will be characterized: oxgyen affinity, BPG binding, and Hbs, and solubility. Actions of promising agents will be studies at a cellular level. Routes and rates of uptake, as well as the rates of hemoglobin modification , will be measured both in intact erythrocyte suspensions, and in whole blood to determine wheather significant plasma protein modification occurs. Memebrance proteins, such as the anion transport protein, will be studied to identify any undersired midifications. Metabolic proterties of trated erythrocytes will be studies: intracelluar, pH, BPG and ATP levels, glucose utilization and lactate production. Physical properties of treated sickle cells will be studies, including red cell dentisity distribution profiles and the percent of sickled forms at oxygen teneions corresponding to those found in the arterial and venous circulation. Cellular studies will be used to develop agents with alternative structurs and reactive groups that may specificity, reduce toxicity, and ehance erythrocyte uptake.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL057604-01A1
Application #
2408208
Study Section
Biophysical Chemistry Study Section (BBCB)
Project Start
1997-08-05
Project End
2001-06-30
Budget Start
1997-08-05
Budget End
1998-06-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Illinois at Chicago
Department
Type
Schools of Pharmacy
DUNS #
121911077
City
Chicago
State
IL
Country
United States
Zip Code
60612
Park, Sunghyouk; Caffrey, Michael S; Johnson, Michael E et al. (2003) Solution structural studies on human erythrocyte alpha-spectrin tetramerization site. J Biol Chem 278:21837-44
Park, Soobong; Hayes, Brittany L; Marankan, Fatima et al. (2003) Regioselective covalent modification of hemoglobin in search of antisickling agents. J Med Chem 46:936-53
Park, Sunghyouk; Johnson, Michael E; Fung, Leslie W-M (2002) Nuclear magnetic resonance studies of mutations at the tetramerization region of human alpha spectrin. Blood 100:283-8
Park, S; Johnson, M E; Fung, L W (2000) NMR analysis of secondary structure and dynamics of a recombinant peptide from the N-terminal region of human erythroid alpha-spectrin. FEBS Lett 485:81-6
Park, S; Wanna, L; Johnson, M E et al. (2000) A mass spectrometry screening method for antiaggregatory activity of proteins covalently modified by combinatorial library members: application to sickle hemoglobin. J Comb Chem 2:314-7
Xu, A S; Ohba, Y; Vida, L et al. (2000) Aspirin acetylation of betaLys-82 of human hemoglobin. NMR study of acetylated hemoglobin Tsurumai. Biochem Pharmacol 60:917-22
Xu, A S; Labotka, R J; London, R E (1999) Acetylation of human hemoglobin by methyl acetylphosphate. Evidence of broad regio-selectivity revealed by NMR studies. J Biol Chem 274:26629-32
Xu, A S; Macdonald, J M; Labotka, R J et al. (1999) NMR study of the sites of human hemoglobin acetylated by aspirin. Biochim Biophys Acta 1432:333-49